Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6WAA

K. pneumoniae Topoisomerase IV (ParE-ParC) in complex with DNA and compound 34 (7-[(1S,5R)-1-amino-3-azabicyclo[3.1.0]hexan-3-yl]-4-(aminomethyl)-1-cyclopropyl-3,6-difluoro-8-methylquinolin-2(1H)-one)

6WAA の概要
エントリーDOI10.2210/pdb6waa/pdb
分子名称DNA topoisomerase 4 subunit B,DNA topoisomerase (ATP-hydrolyzing) chimera, DNA (5'-D(*TP*TP*AP*CP*GP*TP*TP*GP*TP*AP*T)-3'), DNA (5'-D(*GP*AP*TP*CP*AP*TP*AP*CP*AP*AP*CP*GP*TP*AP*A)-3'), ... (8 entities in total)
機能のキーワードdna-topoisomerase, isomerase-dna-isomerase inhibitor complex, isomerase/dna/isomerase inhibitor
由来する生物種Klebsiella pneumoniae 342
詳細
タンパク質・核酸の鎖数12
化学式量合計371367.74
構造登録者
Noeske, J.,Shu, W.,Bellamacina, C. (登録日: 2020-03-24, 公開日: 2020-07-15, 最終更新日: 2024-12-25)
主引用文献Skepper, C.K.,Armstrong, D.,Balibar, C.J.,Bauer, D.,Bellamacina, C.,Benton, B.M.,Bussiere, D.,De Pascale, G.,De Vicente, J.,Dean, C.R.,Dhumale, B.,Fisher, L.M.,Fuller, J.,Fulsunder, M.,Holder, L.M.,Hu, C.,Kantariya, B.,Lapointe, G.,Leeds, J.A.,Li, X.,Lu, P.,Lvov, A.,Ma, S.,Madhavan, S.,Malekar, S.,McKenney, D.,Mergo, W.,Metzger, L.,Moser, H.E.,Mutnick, D.,Noeske, J.,Osborne, C.,Patel, A.,Patel, D.,Patel, T.,Prajapati, K.,Prosen, K.R.,Reck, F.,Richie, D.L.,Rico, A.,Sanderson, M.R.,Satasia, S.,Sawyer, W.S.,Selvarajah, J.,Shah, N.,Shanghavi, K.,Shu, W.,Thompson, K.V.,Traebert, M.,Vala, A.,Vala, L.,Veselkov, D.A.,Vo, J.,Wang, M.,Widya, M.,Williams, S.L.,Xu, Y.,Yue, Q.,Zang, R.,Zhou, B.,Rivkin, A.
Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria.
J.Med.Chem., 63:7773-7816, 2020
Cited by
PubMed Abstract: Since their discovery over 5 decades ago, quinolone antibiotics have found enormous success as broad spectrum agents that exert their activity through dual inhibition of bacterial DNA gyrase and topoisomerase IV. Increasing rates of resistance, driven largely by target-based mutations in the GyrA/ParC quinolone resistance determining region, have eroded the utility and threaten the future use of this vital class of antibiotics. Herein we describe the discovery and optimization of a series of 4-(aminomethyl)quinolin-2(1)-ones, exemplified by , that inhibit bacterial DNA gyrase and topoisomerase IV and display potent activity against ciprofloxacin-resistant Gram-negative pathogens. X-ray crystallography reveals that occupies the classical quinolone binding site in the topoisomerase IV-DNA cleavage complex but does not form significant contacts with residues in the quinolone resistance determining region.
PubMed: 32634310
DOI: 10.1021/acs.jmedchem.0c00347
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (3.2 Å)
構造検証レポート
Validation report summary of 6waa
検証レポート(詳細版)ダウンロードをダウンロード

238895

件を2025-07-16に公開中

PDB statisticsPDBj update infoContact PDBjnumon